



Cite this: DOI: 10.1039/c5ob01574j

Convenient synthesis of α,β -unsaturated γ -butyrolactones and γ -butyrolactams *via* decarboxylative iodination of paraconic acids and β -carboxyl- γ -butyrolactams using 1,3-diiodo-5,5-dimethylhydantoin[†]

Supasorn Phae-nok, Chutima Kuhakarn, Manat Pohmakotr, Vichai Reutrakul and Darunee Soorukram*

A convenient synthetic approach to α,β -unsaturated γ -butyrolactones and α,β -unsaturated γ -butyrolactams is developed. The reaction proceeds *via* decarboxylative iodination of paraconic acids and β -carboxyl- γ -butyrolactams, employing 1,3-diiodo-5,5-dimethylhydantoin (DIH) under irradiation, followed by dehydroiodination of β -iodo- γ -butyrolactones and γ -butyrolactams providing good yields of α,β -unsaturated γ -butyrolactones and γ -butyrolactams, which are synthetically useful building blocks in organic synthesis.

Received 29th July 2015,
Accepted 15th September 2015

DOI: 10.1039/c5ob01574j

www.rsc.org/obc

Introduction

Five-membered ring heterocycles are an important class of compounds. In particular, α,β -unsaturated γ -butyrolactones (or butenolides) and α,β -unsaturated γ -butyrolactams are among advanced synthetic intermediates that find major applications in medicinal chemistry and organic synthesis. They have been used in a range of reactions, such as vinylogous additions to electrophiles,¹ conjugate additions,² and pericyclic reactions.³ The ubiquity of α,β -unsaturated γ -butyrolactones and α,β -unsaturated γ -butyrolactams has been highlighted in naturally occurring compounds, for example, rollicosin,^{4c} (-)-incrustoprine,⁴ⁱ spirofragilide, labdadienolide A, and (+)-erysotramidine that possess important biological properties including antibiotic, antitumor, anti-inflammatory, and anti-HIV activities (Fig. 1).⁴ Not surprisingly, the development of efficient synthetic routes for the preparation of α,β -unsaturated γ -butyrolactones and γ -butyrolactams has been an area of long-standing importance to synthetic chemists.⁵

Among several synthetic routes, the oxidative decarboxylation of aliphatic carboxylic acids is an important and useful conversion to access alkenes. The existing methods usually require $\text{Pb}(\text{OAc})_4/\text{Cu}(\text{OAc})_2$ for mediating oxidative elimination





Fig. 1 Natural compounds containing α,β -unsaturated γ -butyrolactone and γ -butyrolactam units.

of the corresponding radical intermediates.⁶ Recently, catalytic decarbonylative or decarboxylative elimination of carboxylic acids to yield alkenes has also received much attention.⁷ In modern organic synthesis, metal-free reactions which avoid the use of heavy metals have been of particular interest. As a consequence, the conversion of carboxylic acids to alkenes *via* a simple consecutive decarboxylative halogenation (halodecarbonylation)⁸ followed by dehydrohalogenation leading to the synthesis of α,β -unsaturated γ -butyrolactones and γ -butyrolactams was investigated. On the basis of our recent report on

Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand. E-mail: darunee.soo@mahidol.ac.th; Fax: +662 354 7151; Tel: +662 201 5148

[†] Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ob01574j



Scheme 1 Proposed synthetic scheme for the synthesis of α,β -unsaturated γ -butyrolactones and γ -butyrolactams from paraconic acids and β -carboxyl- γ -butyrolactams.

decarboxylative fluorination,⁹ it was envisaged that paraconic acids and β -carboxyl- γ -butyrolactams **1** would undergo decarboxylative iodination to give β -iodo- γ -butyrolactones **2** which, after dehydroiodination, would provide α,β -unsaturated γ -butyrolactones and γ -butyrolactams **3** (Scheme 1). Inspired by the work reported by Gandelman and co-workers on decarboxylative iodination, employing commercially available 1,3-diiido-5,5-dimethylhydantoin (DIH)¹⁰ as an initiator and iodine source,¹¹ we describe herein a convenient synthetic approach to α,β -unsaturated γ -butyrolactones and γ -butyrolactams *via* decarboxylative iodination of paraconic acids and β -carboxyl- γ -butyrolactams using DIH under irradiative conditions followed by base-promoted dehydroiodination (Scheme 1). Notably, DIH has been extensively explored by Togo and others.¹² However, to the best of our knowledge, the use of DIH for decarboxylative iodination followed by base mediated dehydroiodination has never been reported.

Results and discussion

Our study commenced with the optimization of reaction conditions using paraconic acid **1a**¹³ as the model substrate. A standard screening of solvents, reaction times and the stoichiometry of reagents was performed (Table 1). Under thermal conditions, **1a** was reacted with DIH (1 equiv.) in refluxing $\text{ClCH}_2\text{CH}_2\text{Cl}$ for 8 h to give β -iodo- γ -butyrolactone **2a** together with a trace amount of α,β -unsaturated γ -butyrolactone **3a** as observed by TLC and ¹H NMR analyses of the crude mixture (68% conversion based on the recovery of **1a**). Without purification, the crude mixture was treated with Et_3N (2 equiv.) in CH_2Cl_2 for 3 h leading to **3a** in 67% yield after chromatographic purification (Table 1, entry 1). We were pleased to observe an improved conversion of **1a** to a mixture of **2a** and **3a** (**2a** : **3a**, 1 : 2, 96% conversion based on the recovery of **1a**) when the reaction was carried out in refluxing $\text{ClCH}_2\text{CH}_2\text{Cl}$ under irradiation of a tungsten lamp (100 W) (Table 1, entry 2). Compound **3a** was obtained in 95% yield after treatment of the crude mixture with Et_3N . The Et_3N -mediated HI elimination was proved necessary since a prolonged reaction time (from 8 h to 13 h) led to the incomplete conversion of **1a** to **3a**; a mixture of **2a** and **3a** was obtained (**2a** : **3a**, 1 : 8, 96% conversion based on the recovery of **1a**). Gratifyingly, it was found that decarboxylative-iodination of **1a** with DIH (1 equiv.) in refluxing $\text{ClCH}_2\text{CH}_2\text{Cl}$ under photolysis reached completion after 30 min and gave **2a** in quantitative yield. Subsequent

Table 1 Optimization of the reaction conditions for the decarboxylative iodination followed by Et_3N -promoted dehydroiodination of **1a**^a

Entry	DIH (equiv.)	Solvent	Time (h)	% Yield of 3a ^b
1 ^c	1	$\text{ClCH}_2\text{CH}_2\text{Cl}$	8	67
2	1	$\text{ClCH}_2\text{CH}_2\text{Cl}$	8	95
3	1	$\text{ClCH}_2\text{CH}_2\text{Cl}$	0.5	92
4	0.5	$\text{ClCH}_2\text{CH}_2\text{Cl}$	1	66
5	1	CH_2Cl_2	0.5	27
6	1	EtOAc	0.5	15
7	1	MeCN	0.5	56

^a Unless stated otherwise, the reaction was carried out using **1a** (0.5 mmol) in a refluxing solvent (2 mL) under irradiation with a 100 W tungsten lamp. ^b Yield of analytically pure **3a** after column chromatography (SiO_2). ^c The reaction was carried out at reflux without irradiation.


treatment of the crude product with Et_3N cleanly provided **3a** in 92% isolated yield (Table 1, entry 3). The yield was drastically lower when DIH was employed in a lesser amount (0.5 equiv.) (Table 1, entry 4). Finally, other simple organic solvents including CH_2Cl_2 , EtOAc and MeCN were screened and $\text{ClCH}_2\text{CH}_2\text{Cl}$ was proved to be the optimal solvent (Table 1, entry 3 *vs.* entries 5–7). At this stage, the optimal reaction conditions for decarboxylative iodination followed by base-promoted dehydroiodination of paraconic acids **1** were established (Table 1, entry 3).¹⁴

With the optimized reaction conditions in hand, we next examined the substrate scope and the results are summarized in Table 2. In general, the reactions of paraconic acids **1a–1m**, containing mono- and dialkyl groups at the γ -position, smoothly underwent DIH-mediated decarboxylative iodination to yield the corresponding β -iodo- γ -butyrolactones **2a–2m**. Following Et_3N promoted HI elimination of the primarily formed β -iodo- γ -butyrolactones **2a–2m** yielded their corresponding α,β -unsaturated γ -butyrolactones **3a–3m** in good yields (81–92% yields) (Table 2, entries 1–13). Among these, the trifluoromethylated butenolide analogue¹⁵ **3k** could also be synthesized (82% yield) (Table 2, entry 11).

For paraconic acid **1n**, bearing a phenyl substituent at the γ -position, treatment of its β -iodo- γ -butyrolactone **2n** with Et_3N according to the standard procedure led to a complex mixture of unidentified products and no trace of **3n** could be detected. These observed results may result from the polymerization of product **3n** under basic conditions. Fortunately, it was found

Table 2 Synthesis of α,β -unsaturated γ -butyrolactones and γ -butyrolactams via DIH-mediated decarboxylative iodination followed by dehydroiodination of paraconic acids and β -carboxyl- γ -butyrolactams

1; X = O, NR		3; X = O, NR			
Entry	Substrate 1	Product 3; yield ^a	Entry	Substrate 1	Product 3; yield ^a
1	 1a	 3a ; 92%	13	 1m	 3m ; 85%
2	 1b	 3b ; 87%	14	 1n	 3n ; 62% ^b
3	 1c	 3c ; 81%	15	 1o	 3o ; 61% ^b
4	 1d	 3d ; 82%	16	 1p	 3p ; 74% ^b
5	 1e	 3e ; 92%	17	 1qf	 3q ; 45%
6	 1f	 3f ; 86%	18	 1r	 3r ; 46%
7	 1g	 3g ; 93%	19	 1s	 3s ; 75%
8	 1h	 3h ; 82%	20	 1t	 3t ; 76%
9	 1i	 3i ; 83%	21	 1u	 3u ; 74%



Scheme 2 Proposed mechanism for decarboxylative iodination-dehydroiodination of paraconic acids and β -carboxyl- γ -butyrolactams.

Conclusions

In conclusion, we have successfully developed a convenient synthetic approach to α,β -unsaturated γ -butyrolactones and γ -butyrolactams from readily available paraconic acids and β -carboxyl- γ -butyrolactams. Decarboxylative iodination of the carboxylic acid precursors using commercially available 1,3-diiido-5,5-dimethylhydantoin (DIH) under irradiation followed by dehydroiodination gave good yields of the desired α,β -unsaturated γ -butyrolactone and γ -butyrolactam products, which are synthetically useful building blocks in organic synthesis and valuable core structures found in biologically active natural compounds.

Experimental

General information

The ^1H NMR spectra were recorded on a Bruker-400 (400 MHz) or a Bruker-500 (500 MHz) spectrometer in CDCl_3 using tetramethylsilane as an internal standard. The ^{13}C NMR spectra were recorded on a Bruker-400 (100 MHz) or a Bruker-500 (125 MHz) spectrometer in CDCl_3 using solvent peaks as an internal standard. The IR spectra were recorded on an ALPHA FTIR spectrometer. The mass spectra were recorded using a Thermo Finnigan Polaris Q mass spectrometer. The high resolution mass spectra were recorded on a HR-TOF-MS Micro-mass model VQ-TOF2 mass spectrometer. Melting points were recorded using a M-565 Büchi melting point apparatus and are uncorrected. Column chromatography was performed using Merck silica gel 60 (0.063–0.200 mm) (Art 7734). 1,2-Dichloroethane ($\text{ClCH}_2\text{CH}_2\text{Cl}$) and dichloromethane (CH_2Cl_2) were distilled over calcium hydride and stored over activated molecular sieves (4 Å). Other common solvents [acetone, CH_2Cl_2 , hexanes, and ethyl acetate (EtOAc)] were distilled before use. Compounds **1** were synthesized according to the literature procedures.¹³

General procedure

A mixture of paraconic acid or β -carboxyl- γ -butyrolactam **1** (0.5 mmol) and DIH (1 equiv.) in 1,2-dichloroethane (2 mL) was heated to reflux under irradiation by a tungsten-filament lamp (100 W) for 30 minutes. The reaction mixture was then cooled down to room temperature, washed with saturated $\text{Na}_2\text{S}_2\text{O}_3$ (20 mL), and extracted with CH_2Cl_2 (3×10 mL). The combined organic layers were washed with saturated NaHCO_3 and brine, dried over anhydrous Na_2SO_4 , and concentrated to give β -iodo- γ -butyrolactones **2**. The obtained crude compounds **2a–2m** and **2r–2x** were dissolved in dry CH_2Cl_2 (2 mL) and treated with Et_3N (2 equiv.). The progress of the reaction was monitored by TLC. After the complete consumption of the starting material, the reaction mixture was passed through a short column (SiO_2 , CH_2Cl_2) to give the products **3a–3m** and **3r–3x**, respectively. Without treatment with Et_3N , the crude compounds **2n–2p** were converted into **3n–3p** and **3n'–3p'** during purification by column chromatography (SiO_2).

1-Oxaspiro[4.5]dec-3-en-2-one (3a). Pale yellow oil; $R_f = 0.44$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.47$ (d, $J = 5.6$ Hz, 1H, CH), 6.01 (d, $J = 5.6$ Hz, 1H, CH), 1.85–1.32 (m, 10H, $5 \times \text{CH}_2$). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.5$ (C), 160.6 (CH), 120.1 (CH), 88.5 (C), 34.6 ($2 \times \text{CH}_2$), 24.6 (CH_2), 22.4 ($2 \times \text{CH}_2$). IR (neat): $\tilde{\nu} = 1744, 1602, 1448, 1209, 1137, 969, 816$. MS: m/z (%) = 153 (4) $[\text{M} + \text{H}]^+$, 152 (6) $[\text{M}]^+$, 149 (100), 135 (12), 121 (16), 95 (38), 81 (32), 57 (30). HRMS (ESI-TOF): calcd for $\text{C}_9\text{H}_{12}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 175.0735; found 175.0733.

1-Oxaspiro[4.4]non-3-en-2-one (3b). Pale yellow oil; $R_f = 0.44$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.39$ (d, $J = 5.6$ Hz, 1H, CH), 6.01 (d, $J = 5.6$ Hz, 1H, CH), 2.08–1.74 (m, 8H, $4 \times \text{CH}_2$). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.5$ (C), 159.0 (CH), 120.2 (CH), 96.8 (C), 36.8 ($2 \times \text{CH}_2$), 24.6 ($2 \times \text{CH}_2$). IR (neat): $\tilde{\nu} = 1738, 1600, 1434, 1153, 934, 817$. MS: m/z (%) = 139 (8) $[\text{M} + \text{H}]^+$, 138 (10) $[\text{M}]^+$, 134 (30), 126 (100), 112 (63), 91 (72), 81 (93), 67 (60), 55 (75). HRMS (ESI-TOF): calcd for $\text{C}_8\text{H}_{10}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 161.0578; found 161.0580.

1-Oxaspiro[4.6]undec-3-en-2-one (3c). Pale yellow oil; $R_f = 0.44$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.48$ (d, $J = 5.6$ Hz, 1H, CH), 5.95 (d, $J = 5.6$ Hz, 1H, CH), 1.96–1.49 (m, 12H, $6 \times \text{CH}_2$). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.6$ (C), 161.5 (CH), 119.1 (CH), 92.0 (C), 37.6 ($2 \times \text{CH}_2$), 28.9 ($2 \times \text{CH}_2$), 22.7 ($2 \times \text{CH}_2$). IR (neat): $\tilde{\nu} = 1744, 1604, 1460, 1240, 1162, 939, 815$. MS: m/z (%) = 126 (62), 91 (100), 79 (89), 66 (51), 55 (45). HRMS (ESI-TOF): calcd for $\text{C}_{10}\text{H}_{14}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 189.0891; found 189.0892.

1-Oxaspiro[4.7]dodec-3-en-2-one (3d). Pale yellow oil; $R_f = 0.40$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.53$ (d, $J = 5.6$ Hz, 1H, CH), 5.99 (d, $J = 5.6$ Hz, 1H, CH), 2.04–1.43 (m, 14H, $7 \times \text{CH}_2$). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.5$ (C), 161.1 (CH), 120.0 (CH), 92.1 (CH), 33.4 ($2 \times \text{CH}_2$), 27.9 ($2 \times \text{CH}_2$), 24.4 (CH_2), 22.4 ($2 \times \text{CH}_2$). IR (neat): $\tilde{\nu} = 1745, 1600, 1465, 1161, 1023, 818$. MS: m/z (%) = 180 (11) $[\text{M}]^+$, 133 (36), 109 (52), 95 (78), 91 (84), 81 (89), 79 (100), 67 (55), 55 (65). HRMS (ESI-TOF): calcd for $\text{C}_{11}\text{H}_{16}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 203.1048; found 203.1049.

5,5-Dimethylfuran-2(5H)-one (3e). Pale yellow oil; $R_f = 0.33$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.41$ (d, $J = 5.6$ Hz, 1H, CH), 5.99 (d, $J = 5.6$ Hz, 1H, CH), 1.49 (s, 6H, $2 \times \text{CH}_3$). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.4$ (C), 161.2 (CH), 119.9 (CH), 86.6 (C), 25.3 ($2 \times \text{CH}_3$). IR (neat): $\tilde{\nu} = 1732, 1461, 1258, 1117, 1016, 795$. MS: m/z (%) = 113 (40) $[\text{M} + \text{H}]^+$, 112 (11) $[\text{M}]^+$, 77 (87), 51 (39). HRMS (ESI-TOF): calcd for $\text{C}_6\text{H}_8\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 135.0422; found 135.0423.

5,5-Diethylfuran-2(5H)-one (3f). Pale yellow oil; $R_f = 0.44$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.29$ (d, $J = 5.7$ Hz, 1H, CH), 6.08 (d, $J = 5.7$ Hz, 1H, CH), 1.88 (dq, $J_2 = 7.3$ Hz, $J_1 = 14.6$ Hz, 2H, CH_2), 1.77 (dq, $J_2 = 7.3$ Hz, $J_1 = 14.6$ Hz, 2H, CH_2), 0.86 (t, $J = 7.3$ Hz, 6H, $2 \times \text{CH}_3$). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.9$ (C), 158.9 (CH), 121.6 (CH), 92.0 (C), 29.5 ($2 \times \text{CH}_2$), 7.7 ($2 \times \text{CH}_3$). IR (neat): $\tilde{\nu} = 1750, 1603, 1460, 1224, 1133, 950, 820$. MS: m/z (%) = 140 (19) $[\text{M}]^+$, 133 (47), 126 (89), 95 (75), 81 (100), 67 (88), 55 (81). HRMS (ESI-TOF): calcd for $\text{C}_8\text{H}_{12}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 163.0735; found 163.0734.

5-Ethyl-5-methylfuran-2(5H)-one (3g). Pale yellow oil; $R_f = 0.40$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.36$ (d, $J = 5.6$ Hz, 1H, CH), 6.03 (d, $J = 5.6$ Hz, 1H, CH), 1.86 (dq, $J_2 = 7.3$ Hz, $J_1 = 14.6$ Hz, 1H, CHH), 1.76 (dq, $J_2 = 7.3$ Hz, $J_1 = 14.6$ Hz, 1H, CHH), 1.47 (s, 3H, CH_3), 0.88 (t, $J = 7.3$ Hz, 3H, CH_3). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.6$ (C), 160.2 (CH), 120.7 (CH), 89.3 (C), 31.2 (CH_2), 23.5 (CH_3), 8.0 (CH_3). IR (neat): $\tilde{\nu} = 1745, 1603, 1459, 1235, 1130, 950, 819$. MS: m/z (%) = 127 (21) $[\text{M} + \text{H}]^+$, 126 (100) $[\text{M}]^+$, 112 (48), 95 (76), 81 (90), 67 (78), 55 (84). HRMS (ESI-TOF): calcd for $\text{C}_7\text{H}_{10}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 149.0578; found 149.0579.

5-Isopropyl-5-methylfuran-2(5H)-one (3h). Pale yellow oil; $R_f = 0.42$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.34$ (d, $J = 5.7$ Hz, 1H, CH), 5.97 (d, $J = 5.7$ Hz, 1H, CH), 1.91 (hept, $J = 6.9$ Hz, 1H, CH), 1.37 (s, 3H, CH_3), 0.91 (d, $J = 6.9$ Hz, 3H, CH_3), 0.88 (d, $J = 6.9$ Hz, 3H, CH_3). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.7$ (C), 159.7 (CH), 120.8 (CH), 91.7 (C), 35.5 (CH), 21.3 (CH_3), 17.7 (CH_3), 17.2 (CH_3). IR (neat): $\tilde{\nu} = 1744, 1603, 1457, 1249, 1120, 948, 819$. MS: m/z (%) = 141 (28) $[\text{M} + \text{H}]^+$, 140 (100) $[\text{M}]^+$, 138 (22). HRMS (ESI-TOF): calcd for $\text{C}_8\text{H}_{12}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 163.0735; found 163.0732.

5-Ethyl-5-phenylfuran-2(5H)-one (3i). Pale yellow oil; $R_f = 0.53$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.63$ (d, $J = 5.6$ Hz, 1H, CH), 7.42–7.28 (m, 5H, ArH), 6.08 (d, $J = 5.6$ Hz, 1H, CH), 2.19 (dq, $J_2 = 7.3$ Hz, $J_1 = 14.6$ Hz, 1H, CHH), 2.03 (dq, $J_2 = 7.3$ Hz, $J_1 = 14.6$ Hz, 1H, CHH), 0.89 (t, $J = 7.3$ Hz, 3H, CH_3). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.4$ (C), 159.2 (CH), 138.8 (C), 128.8 ($2 \times \text{CH}$), 128.1 (CH), 125.0 ($2 \times \text{CH}$), 120.0 (CH), 91.9 (C), 32.7 (CH_2), 8.0 (CH_3). IR (neat): $\tilde{\nu} = 3085, 3066, 1752, 1601, 1448, 1210, 1121, 1024, 816, 760, 698$. MS: m/z (%) = 189 (7) $[\text{M} + \text{H}]^+$, 188 (12) $[\text{M}]^+$, 159 (100), 131 (53), 103 (63), 77 (58), 67 (14), 55 (9). HRMS (ESI-TOF): calcd for $\text{C}_{12}\text{H}_{12}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 211.0735; found 211.0733.

5-Methyl-5-phenylfuran-2(5H)-one (3j). Pale yellow oil; $R_f = 0.38$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.57$ (d, $J = 5.6$ Hz, 1H, CH), 7.35–7.29 (m, 4H, ArH), 7.29–7.22 (m, 1H, ArH), 5.99 (d, $J = 5.6$ Hz, 1H, CH), 1.76 (s, 3H, CH_3). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 172.4$ (C), 160.4 (CH), 139.2 (C), 128.8

($2 \times \text{CH}$), 128.3 (CH), 124.7 ($2 \times \text{CH}$), 119.3 (CH), 88.9 (C), 26.3 (CH_3). IR (neat): $\tilde{\nu} = 3087, 1747, 1447, 765, 697$. MS: m/z (%) = 175 (4) $[\text{M} + \text{H}]^+$, 174 (9) $[\text{M}]^+$, 159 (39), 131 (100), 103 (78), 77 (51). HRMS (ESI-TOF): calcd for $\text{C}_{11}\text{H}_{10}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 197.0578; found 197.0578.

5-Phenyl-5-(trifluoromethyl)furan-2(5H)-one (3k). White solid; mp 70–72 °C (CH_2Cl_2); $R_f = 0.61$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.82$ (d, $J = 5.7$ Hz, 1H, CH), 7.61–7.52 (m, 2H, ArH), 7.51–7.40 (m, 3H, ArH), 6.39 (d, $J = 5.7$ Hz, 1H, CH). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 169.7$ (C), 150.8 (CH), 130.9 (C), 130.2 (CH), 130.0 ($3 \times \text{CH}$), 126.6 (CH), 124.2 (CH), 122.4 (q, $J = 280.3$ Hz, CF_3), 87.4 (q, $J = 32.2$ Hz, C). ^{19}F NMR (376 MHz, CDCl_3): $\delta = -76.9$ (s, 3 F). IR (neat): $\tilde{\nu} = 3117, 1797, 1775, 1292, 1171, 761, 694$. MS: m/z (%) = 228 (1) $[\text{M}]^+$, 159 (100), 131 (48), 103 (43), 77 (26). HRMS (ESI-TOF): calcd for $\text{C}_{11}\text{H}_7\text{F}_3\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 251.0296; found 251.0296.

5-Butylfuran-2(5H)-one (3l). Pale yellow oil; $R_f = 0.44$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.47$ (dd, $J_2 = 1.3$ Hz, $J_2 = 5.7$ Hz, 1H, CH), 6.11 (dd, $J_3 = 1.9$ Hz, $J_2 = 5.7$ Hz, 1H, CH), 5.08–5.01 (m, 1H, CH), 1.84–1.81 (m, 2H, CH_2), 1.50–1.30 (m, 4H, $2 \times \text{CH}_2$), 0.92 (t, $J = 7.1$ Hz, 3H, CH_3). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 173.2$ (C), 156.3 (CH), 121.5 (CH), 83.4 (C), 32.8 (CH_2), 27.0 (CH_2), 22.4 (CH_2), 13.8 (CH_3). IR (neat): $\tilde{\nu} = 1747, 1601, 1466, 1162, 1024, 818$. MS: m/z (%) = 140 (17) $[\text{M}]^+$, 133 (40), 95 (90), 81 (100), 67 (89), 55 (98). HRMS (ESI-TOF): calcd for $\text{C}_8\text{H}_{12}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 163.0735; found 163.0729.

5-Phenethylfuran-2(5H)-one (3m). Pale yellow oil; $R_f = 0.48$ (CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): $\delta = 7.40$ (dd, $J_2 = 1.4$ Hz, $J_2 = 5.7$ Hz, 1H, CH), 7.34–7.27 (m, 2H, ArH), 7.25–7.17 (m, 3H, ArH), 6.11 (dd, $J_3 = 2.0$ Hz, $J_2 = 5.7$ Hz, 1H, CH), 5.05–4.98 (m, 1H, CH), 2.90–2.72 (m, 2H, CH_2), 2.14–2.03 (m, 1H, CHH), 2.00–1.88 (m, 1H, CHH). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 173.0$ (C), 156.1 (CH), 140.2 (C), 128.6 ($2 \times \text{CH}$), 128.5 ($2 \times \text{CH}$), 126.4 (CH), 121.6 (CH), 82.4 (C), 34.9 (CH_2), 31.3 (CH_2). IR (neat): $\tilde{\nu} = 3085, 3062, 1744, 1601, 1454, 1159, 1102, 815, 752, 699$. MS: m/z (%) = 189 (9) $[\text{M} + \text{H}]^+$, 188 (10) $[\text{M}]^+$, 178 (14), 105 (24), 97 (38), 91 (100), 77 (34), 65 (24), 55 (16). HRMS (ESI-TOF): calcd for $\text{C}_{12}\text{H}_{12}\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 211.0735; found 211.0738.

5-Phenylfuran-2(5H)-one (3n) and 5-phenylfuran-2(3H)-one (3n'). A 2 : 1 mixture of **3n** and **3n'** was obtained as an orange semi-solid after column chromatography (SiO_2 , 20% EtOAc in hexanes). **3n**; $R_f = 0.20$ (20% EtOAc in hexanes), **3n'**; $R_f = 0.38$ (20% EtOAc in hexanes); ^1H NMR (400 MHz, CDCl_3 , integrated equally for both isomers): $\delta = 7.56$ –7.50 (m, 2H, ArH of **3n'**), 7.46 (dd, $J_2 = 1.6$ Hz, $J_2 = 5.6$ Hz, 1H, CH of **3n**), 7.37–7.26 (each m, 3H, ArH of **3n** and 3H, ArH of **3n'**), 7.23–7.16 (m, 2H, ArH of **3n**), 6.16 (dd, $J_3 = 2.1$ Hz, $J_2 = 5.6$ Hz, 1H, CH of **3n**), 5.97–5.92 (m, 1H, CH of **3n**), 5.72 (t, $J = 2.7$ Hz, 1H, CH of **3n'**), 3.35 (d, $J = 2.7$ Hz, 2H, CH_2 of **3n'**). ^{13}C NMR (100 MHz, CDCl_3): $\delta = 175.9$ (C of **3n'**), 173.1 (C of **3n**), 155.8 (CH of **3n**), 153.9 (C of **3n'**), 134.2 (1C of **3n** and 1C of **3n'**), 129.3 (CH of **3n**), 129.6 (CH of **3n'**), 128.6 ($2 \times \text{CH}$ of **3n'**), 129.0 ($2 \times \text{CH}$ of **3n**), 126.5 ($2 \times \text{CH}$ of **3n**), 124.7 ($2 \times \text{CH}$ of **3n'**), 120.9 (CH of **3n**), 97.6 (CH of **3n'**), 84.3 (CH of **3n**), 34.6 (CH_2 of **3n'**). IR (neat): $\tilde{\nu} = 3090, 3034, 1746, 1454, 1154, 1028, 760, 697$. MS: m/z (%) = 161 (15) $[\text{M} + \text{H}]^+$, 160 (87) $[\text{M}]^+$, 131 (99), 103 (70), 77

(100). HRMS (ESI-TOF): calcd for $C_{10}H_8O_2Na [M + Na]^+$ 183.0422; found 183.0430.

5-(*p*-Tolyl)furan-2(5*H*)-one (3o) and 5-(*p*-tolyl)furan-2(3*H*)-one (3o'). A 10:1 mixture of **3o** and **3o'** was obtained as an orange solid after column chromatography (SiO_2 , 20% EtOAc in hexanes). **3o**; $R_f = 0.33$ (20% EtOAc in hexanes), **3o'**; $R_f = 0.47$ (20% EtOAc in hexanes); mp 49–52 °C (CH_2Cl_2). 1H NMR (500 MHz, $CDCl_3$, integrated equally for both isomers): $\delta = 7.49$ (dd, $J_2 = 1.6$ Hz, $J_2 = 5.6$ Hz, 1H, CH of **3o**), 7.20 (each d, $J = 8.1$ Hz, 2H, ArH of **3o** and 2H, ArH of **3o'**), 7.14 (each d, $J = 8.1$ Hz, 2H, ArH of **3o** and 2H, ArH of **3o'**), 6.20 (dd, $J_3 = 2.1$ Hz, $J_2 = 5.6$ Hz, 1H, CH of **3o**), 5.97 (br s, 1H, CH of **3o**), 5.70 (t, $J = 2.7$ Hz, 1H, CH of **3o'**), 3.39 (d, $J = 2.7$ Hz, 2H, CH_2 of **3o'**), 2.37 (s, 3H, CH_3 of **3o'**), 2.36 (s, 3H, CH_3 of **3o**). ^{13}C NMR (125 MHz, $CDCl_3$): $\delta = 173.1$ (C of **3o**), 173.0 (C of **3o'**), 155.8 (CH of **3o**), 155.7 (C of **3o'**), 139.4 (C of **3o**), 138.9 (C of **3o'**), 131.3 (C of **3o'**), 131.2 (C of **3o**), 129.7 (2 × CH of **3o**), 129.4 (2 × CH of **3o'**), 126.5 (2 × CH of **3o**), 124.7 (2 × CH of **3o'**), 121.0 (CH of **3o**), 96.6 (CH of **3o'**), 84.4 (CH of **3o**), 34.6 (CH_2 of **3o'**), 21.2 (CH_3 of **3o**), 21.1 (CH_3 of **3o'**). IR (neat): $\tilde{\nu} = 3080, 3038, 1795, 1748, 1512, 1306, 1158, 819$. MS: m/z (%) = 175 (10) $[M + H]^+$, 174 (52) $[M]^+$, 145 (100), 115 (94), 91 (80), 65 (34). HRMS (ESI-TOF): calcd for $C_{11}H_{10}O_2Na [M + Na]^+$ 197.0578; found 197.0572.

5-(4-Chlorophenyl)furan-2(5*H*)-one (3p) and 5-(4-chlorophenyl)furan-2(3*H*)-one (3p'). A 1:4 mixture of **3p** and **3p'** was obtained as an orange semi-solid after column chromatography (SiO_2 , 20% EtOAc in hexanes). **3p**; $R_f = 0.16$ (20% EtOAc in hexanes), **3p'**; $R_f = 0.33$ (20% EtOAc in hexanes); 1H NMR (400 MHz, $CDCl_3$, integrated equally for both isomers): $\delta = 7.47$ (d, $J = 8.6$ Hz, 2H, ArH of **3p'**), 7.44 (dd, $J_2 = 1.6$ Hz, $J_2 = 5.6$ Hz, 1H, CH of **3p**), 7.31 (each d, $J = 8.6$ Hz, 2H, ArH of **3p** and 2H, ArH of **3p'**), 7.14 (d, $J = 8.4$ Hz, 2H, ArH of **3p**), 6.18 (dd, $J_3 = 2.1$ Hz, $J_2 = 5.6$ Hz, 1H, CH of **3p**), 5.92 (br s, 1H, CH of **3p**), 5.72 (t, $J = 2.7$ Hz, 1H, CH of **3p'**), 3.36 (d, $J = 2.7$ Hz, 2H, CH_2 of **3p'**). ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 175.5$ (C of **3p'**), 172.7 (C of **3p**), 155.3 (CH of **3p**), 153.0 (C of **3p'**), 135.5 (C of **3p'**), 135.3 (C of **3p**), 132.8 (C of **3p**), 129.3 (2 × CH of **3p**), 129.0 (2 × CH of **3p'**), 127.8 (2 × CH of **3p**), 126.8 (C of **3p'**), 126.0 (2 × CH of **3p'**), 121.3 (CH of **3p**), 98.2 (CH of **3p'**), 83.5 (CH of **3p**), 34.6 (CH_2 of **3p'**). IR (neat): $\tilde{\nu} = 3031, 1746, 1682, 1514, 1157, 812$. MS: m/z (%) = 195 (13) $[M + H]^+$, 194 (86) $[M]^+$, 159 (100), 139 (77), 103 (53), 74 (58). HRMS (ESI-TOF): calcd for $C_{10}H_7ClO_2Na [M + Na]^+$ 217.0032; found 217.0028.

5-(4-Chlorophenyl)-3-methylfuran-2(5*H*)-one (3q). A white solid was obtained after column chromatography (SiO_2 , 50% CH_2Cl_2 in hexanes). $R_f = 0.29$ (20% EtOAc in hexanes); mp 83–86 °C (CH_2Cl_2). 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.29$ (d, $J = 8.5$ Hz, 2H, ArH), 7.14 (d, $J = 8.4$ Hz, 2H, ArH), 7.03 (dd, $J_3 = 1.7$ Hz, $J_2 = 1.7$ Hz, 1H, CH), 5.77 (dd, $J_4 = 1.7$ Hz, $J_2 = 1.7$ Hz, 1H, CH), 1.93 (dd, $J_4 = 1.7$ Hz, $J_3 = 1.7$ Hz, 3H, CH_3). ^{13}C NMR (400 MHz, $CDCl_3$): $\delta = 174.0$ (C), 147.8 (CH), 135.0 (C), 133.6 (C), 129.9 (C), 129.2 (2 × CH), 127.8 (2 × CH), 81.3 (CH), 10.6 (CH_3). IR (neat): $\tilde{\nu} = 3064, 1743, 1492, 1042, 823$. MS: m/z (%) = 210 (11) $[M + H]^+$, 179 (100), 150 (46), 122 (33), 96 (40), 82 (76), 55 (56). HRMS (ESI-TOF): calcd for $C_{11}H_9ClO_2Na [M + Na]^+$ 231.0189; found 231.0182.

1-Phenyl-1*H*-pyrrol-2(5*H*)-one (3r). Pale yellow solid; mp 81–85 °C (CH_2Cl_2); $R_f = 0.24$ (10% EtOAc in hexanes). 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.68$ –7.61 (m, 2H, ArH), 7.36–7.28 (m, 2H, ArH), 7.12 (dt, $J_2 = 1.9$ Hz, $J_2 = 6.0$ Hz, 1H, CH), 7.10–7.04 (m, 1H, ArH), 6.22 (dt, $J_3 = 1.9$ Hz, $J_2 = 6.0$ Hz, 1H, CH), 4.39 (dd, $J_3 = 1.9$ Hz, $J_2 = 1.9$ Hz, 2H, CH_2). ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 170.2$ (C), 142.2 (CH), 139.0 (C), 129.3 (CH), 129.1 (2 × CH), 124.2 (CH), 118.9 (2 × CH), 53.2 (CH_2). IR (neat): $\tilde{\nu} = 3350, 3079, 3043, 1681, 1596, 753, 689$. MS: m/z (%) = 160 (6) $[M + H]^+$, 159 (38) $[M]^+$, 130 (100), 77 (33). HRMS (ESI-TOF): calcd for $C_{10}H_9NONa [M + Na]^+$ 182.0582; found 182.0582.

1-Benzyl-1*H*-pyrrol-2(5*H*)-one (3s). Pale yellow oil; $R_f = 0.22$ (20% EtOAc in hexanes). 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.37$ –7.19 (m, 5H, ArH), 7.06 (dt, $J_2 = 1.7$ Hz, $J_2 = 6.0$ Hz, 1H, CH), 6.23 (dt, $J_3 = 1.8$ Hz, $J_2 = 6.0$ Hz, 1H, CH), 4.64 (s, 2H, CH_2Ph), 3.88 (br s, 2H, CH_2). ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 171.4$ (C), 142.8 (CH), 137.2 (C), 128.7 (2 × CH), 127.9 (3 × CH), 127.5 (CH), 52.2 (CH_2), 45.9 (CH_2). IR (neat): $\tilde{\nu} = 3368, 3063, 3030, 1659, 1450, 717, 699$. MS: m/z (%) = 174 (6) $[M + H]^+$, 173 (50) $[M]^+$, 172 (72), 106 (40), 91 (100), 77 (27), 65 (34). HRMS (ESI-TOF): calcd for $C_{11}H_{11}NONa [M + Na]^+$ 196.0738; found 196.0734.

1-Benzyl-5-phenyl-1*H*-pyrrol-2(5*H*)-one (3t) and 1-benzyl-5-phenyl-1*H*-pyrrol-2(3*H*)-one (3t'). A 3:2 mixture of **3t** and **3t'** was obtained as a pale brown viscous oil. **3t**; $R_f = 0.36$ (30% acetone in hexanes), **3t'**; $R_f = 0.42$ (30% acetone in hexanes); 1H NMR (400 MHz, $CDCl_3$, integrated equally for both isomers): $\delta = 7.42$ –7.24 (each, m, 5H, ArH of **3t** and 5H, ArH of **3t'**), 7.23–7.14 (each, m, 1H, ArH of **3t** and 3H, ArH of **3t'**), 7.14–7.09 (m, 2H, ArH of **3t**), 7.09–7.04 (m, 2H, ArH of **3t**), 6.99–6.94 (m, 2H, ArH of **3t'**), 7.01 (dd, $J_2 = 1.6$ Hz, $J_2 = 5.8$ Hz, 1H, CH of **3t**), 6.28 (dd, $J_3 = 1.6$ Hz, $J_2 = 5.8$ Hz, 1H, CH of **3t**), 5.27 (t, $J = 2.6$ Hz, 1H, CH of **3t'**), 5.19 (d, $J = 15.0$ Hz, 1H, $CHHPh$ of **3t**), 4.88 (br s, 1H, CH of **3t**), 4.68 (s, 2H, CH_2Ph of **3t'**), 3.60 (d, $J = 15.0$ Hz, 1H, $CHHPh$ of **3t**), 3.27 (d, $J = 2.6$ Hz, 2H, CH_2 of **3t'**). ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 178.4$ (C of **3t'**), 171.3 (C of **3t**), 148.1 (CH of **3t**), 146.2 (C of **3t'**), 137.5 (C of **3t'**), 137.3 (C of **3t**), 134.4 (C of **3t**), 131.7 (C of **3t'**), 129.2 (2 × CH of **3t**), 128.9 (CH of **3t'**), 128.8 (2 × CH of **3t'**), 128.7 (2 × CH of **3t**), 128.4 (4 × CH of **3t'**), 128.3 (CH of **3t**), 128.2 (2 × CH of **3t**), 127.5 (2 × CH of **3t** and 2 × CH of **3t'**), 127.2 (CH of **3t**), 127.1 (CH of **3t'**), 126.2 (CH of **3t**), 102.4 (CH of **3t'**), 65.8 (CH of **3t**), 44.3 (CH_2 of **3t'**), 43.4 (CH_2 of **3t**), 37.3 (CH_2 of **3t'**). IR (neat): $\tilde{\nu} = 3306, 3061, 3029, 1677, 1453, 843, 768, 698$. MS: m/z (%) = 250 (4) $[M + H]^+$, 249 (22) $[M]^+$, 144 (100), 115 (43), 91 (18), 77 (8). HRMS (ESI-TOF): calcd for $C_{17}H_{15}NONa [M + Na]^+$ 272.1051; found 272.1053.

1-Benzyl-5-(*p*-tolyl)-1*H*-pyrrol-2(5*H*)-one (3u). Pale brown viscous oil; $R_f = 0.26$ (30% EtOAc in hexanes). 1H NMR (400 MHz, $CDCl_3$): $\delta = 7.26$ –7.15 (m, 3H, ArH), 7.10 (d, $J = 7.8$ Hz, 2H, ArH), 7.05 (d, $J = 6.6$ Hz, 2H, ArH), 6.91 (dd, $J_2 = 1.5$ Hz, $J_2 = 5.9$ Hz, 1H, CH), 6.88 (d, $J = 8.0$ Hz, 2H, ArH), 6.19 (dd, $J_3 = 1.7$ Hz, $J_2 = 5.9$ Hz, 1H, CH), 5.10 (d, $J = 14.9$ Hz, 1H, $CHHPh$), 4.77 (br s, 1H, CH), 3.51 (d, $J = 14.9$ Hz, 1H, $CHHPh$), 2.29 (s, 3H, CH_3). ^{13}C NMR (100 MHz, $CDCl_3$): $\delta = 171.3$ (C), 148.2 (CH), 138.7 (C), 137.4 (C), 131.2 (C), 129.8 (2 × CH), 128.6

(2 × CH), 128.2 (2 × CH), 127.4 (3 × CH), 126.1 (CH), 65.6 (CH), 43.3 (CH₂), 21.2 (CH₃). IR (neat): $\tilde{\nu}$ = 3306, 3029, 1665, 1437, 816, 756, 700. MS: m/z (%) = 264 (4) [M + H]⁺, 263 (12) [M]⁺, 158 (100), 129 (33), 115 (26), 91 (18), 77 (5). HRMS (ESI-TOF): calcd for C₁₈H₁₇NONa [M + Na]⁺ 286.1208; found 286.1215.

1-Benzyl-5-(4-methoxyphenyl)-1H-pyrrol-2(5H)-one (3v). Pale brown viscous oil; R_f = 0.32 (40% EtOAc in hexanes). ¹H NMR (400 MHz, CDCl₃): δ = 7.35–7.19 (m, 1H of CH and 2H of ArH), 7.15–7.08 (m, 2H, ArH), 7.03–6.95 (m, 3H, ArH), 6.92–6.86 (m, 2H, ArH), 6.26 (dd, J_3 = 1.7 Hz, J_2 = 5.8 Hz, 1H, CH), 5.16 (d, J = 15.0 Hz, 1H, CHHP), 4.84 (br s, 1H, CH), 3.82 (s, 3H, OCH₃), 3.58 (d, J = 15.0 Hz, 1H, CHHP). ¹³C NMR (100 MHz, CDCl₃): δ = 171.2 (C), 159.9 (C), 148.3 (CH), 137.4 (C), 128.8 (2 × CH), 128.6 (2 × CH), 127.4 (CH), 126.1 (CH), 125.9 (C), 114.5 (2 × CH), 65.3 (CH), 53.3 (CH₃), 43.3 (CH₂). IR (neat): $\tilde{\nu}$ = 3306, 3104, 3064, 3023, 1670, 1510, 1238, 1023, 830, 765, 699. MS: m/z (%) = 280 (16) [M + H]⁺, 279 (87) [M]⁺, 188 (67), 174 (100), 131 (26), 91 (47). HRMS (ESI-TOF): calcd for C₁₈H₁₇NO₂Na [M + Na]⁺ 302.1157; found 302.1161.

3-Methyl-1-phenyl-1H-pyrrol-2(5H)-one (3w). White solid; mp 81–83 °C (EtOAc/hexanes); R_f = 0.33 (30% EtOAc in hexanes). ¹H NMR (400 MHz, CDCl₃): δ = 7.78–7.71 (m, 2H, ArH), 7.44–7.33 (m, 2H, ArH), 7.16–7.08 (m, 1H, ArH), 6.82–6.76 (m, 1H, CH), 4.33–4.27 (m, 2H, CH₂), 1.99–1.93 (m, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 170.8 (C), 139.5 (C), 136.8 (C), 134.7 (CH), 129.0 (2 × CH), 123.9 (CH), 118.4 (2 × CH), 50.8 (CH₂), 11.3 (CH₃). IR (neat): $\tilde{\nu}$ = 3062, 3041, 1671, 1595, 1496, 1380, 758, 690. MS: m/z (%) = 174 (14) [M + H]⁺, 173 (28) [M]⁺, 144 (65), 121 (29), 91 (40), 79 (54). HRMS (ESI-TOF): calcd for C₁₁H₁₁NONa [M + Na]⁺ 196.0738; found 196.0730.

1-Benzyl-5-(4-methoxyphenyl)-3-methyl-1H-pyrrol-2(5H)-one (3x). Light brown viscous oil; R_f = 0.36 (30% EtOAc in hexanes). ¹H NMR (400 MHz, CDCl₃): δ = 7.33–7.21 (m, 3H, ArH), 7.15–7.08 (m, 2H, ArH), 6.99–6.93 (m, 2H, ArH), 6.91–6.84 (m, 2H, ArH), 6.63–6.58 (m, 1H, CH), 5.15 (d, J = 14.9 Hz, 1H, CHHP), 4.72–4.66 (m, 1H, CH), 3.82 (s, 3H, CH₃), 3.60 (d, J = 14.9 Hz, 1H, CHHP) 2.02–1.98 (m, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃): δ = 171.9 (C), 159.7 (C), 141.2 (CH), 137.6 (C), 133.9 (C), 128.7 (2 × CH), 128.6 (2 × CH), 128.2 (2 × CH), 127.3 (CH), 127.0 (C), 114.4 (2 × CH), 63.1 (CH), 55.3 (CH₃), 43.7 (CH₂), 11.2 (CH₃). IR (neat): $\tilde{\nu}$ = 3064, 3031, 1678, 1608, 1510, 1242, 1030, 831, 705. MS: m/z (%) = 294 (33) [M + H]⁺, 293 (100) [M]⁺, 202 (77), 188 (61), 145 (24), 91 (37). HRMS (ESI-TOF): calcd for C₁₉H₁₉NO₂Na [M + Na]⁺ 316.1313; found 316.1337.

Acknowledgements

The authors acknowledge financial support from the Thailand Research Fund (RSA5880013), the Office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative, and the Center of Excellence for Innovation in Chemistry (PERCH-CIC). Nakhon Ratchasima Rajabhat University's Academic Development

Fund (4-2555) is also gratefully acknowledged for a scholarship to S.P.

Notes and references

- See, for example: (a) C. Curti, A. Sartori, L. Battistini, G. Rasso, P. Burreddu, F. Zanardi and G. Casiraghi, *J. Org. Chem.*, 2008, **73**, 5446; (b) C. Curti, L. Battistini, F. Zanardi, G. Rasso, V. Zambrano, L. Pinna and G. Casiraghi, *J. Org. Chem.*, 2010, **75**, 8681; (c) R. P. Singh, B. M. Foxman and L. Deng, *J. Am. Chem. Soc.*, 2010, **132**, 9558; (d) H. Huang, F. Yu, Z. Jin, W. Li, W. Wu, X. Liang and J. Ye, *Chem. Commun.*, 2010, **46**, 5957; (e) S. V. Pansare and E. K. Paul, *Chem. Commun.*, 2011, **47**, 1027; (f) V. Kumar and S. Mukherjee, *Chem. Commun.*, 2013, **49**, 11203; (g) Y.-L. Guo, L.-N. Jia, L. Peng, L.-W. Qi, J. Zhou, F. Tian, X.-Y. Xu and L.-X. Wang, *RSC Adv.*, 2013, **3**, 16973; (h) Y.-R. Chen, U. Das, M.-H. Liu and W. Lin, *J. Org. Chem.*, 2015, **80**, 1985; (i) S. Nakamura, R. Yamaji and M. Hayashi, *Chem. – Eur. J.*, 2015, **21**, 9615.
- See, for example: (a) A. G. M. Barrett, J. Head, M. L. Smith, N. S. Stock, A. J. P. White and D. J. Williams, *J. Org. Chem.*, 1999, **64**, 6005; (b) A. Gheorghie, M. Schulte and O. Reiser, *J. Org. Chem.*, 2006, **71**, 2173; (c) J. F. Bower, S. Chakthong, J. Švende, A. J. Williams, R. M. Lawrence, P. Szeto and T. Gallagher, *Org. Biomol. Chem.*, 2006, **4**, 1868; (d) O. Ahmed, P. B. Hitchcock and D. W. Young, *Org. Biomol. Chem.*, 2006, **4**, 1596.
- See, for example: (a) N. Langlois, N. Van Bac, N. Dahuron, J.-M. Delcroix, A. Deyine, D. Griffart-Brunet, A. Chiaroni and C. Riche, *Tetrahedron*, 1995, **51**, 3571; (b) P. J. Dransfield, S. Wang, A. Dilley and D. Romo, *Org. Lett.*, 2005, **7**, 1679.
- See, for example: (a) F. Q. Alali, X.-X. Liu and J. L. McLaughlin, *J. Nat. Prod.*, 1999, **62**, 504; (b) M. Pour, M. Špulák, V. Buchta, P. Kubanová, M. Vopršalová, V. Wsól, H. Fáková, P. Koudelka, H. Pourová and R. Schiller, *J. Med. Chem.*, 2001, **44**, 2701; (c) C.-C. Liaw, F.-R. Chang, M.-J. Wu and Y.-C. Wu, *J. Nat. Prod.*, 2003, **66**, 279; (d) A. D. Wright, R. de Nys, C. K. Angerhofer, J. M. Pezzuto and M. Gurrath, *J. Nat. Prod.*, 2006, **69**, 1180; (e) T. Montagnon, M. Tofi and G. Vassilikogiannakis, *Acc. Chem. Res.*, 2008, **41**, 1001; (f) V. E. J. Hikawczuk, J. R. Saad, O. S. Giordano, C. García, T. Martín, V. S. Martín, M. E. Sosa and C. E. Tonn, *J. Nat. Prod.*, 2008, **71**, 190; (g) R. R. Parvatkar, C. D'Souza, A. Triphthi and C. G. Naik, *Phytochemistry*, 2009, **70**, 128; (h) X. Li, X.-Q. Li, H.-M. Liu, X.-Z. Zhou and Z.-H. Shao, *Org. Med. Chem. Lett.*, 2012, **2**, 26; (i) D. Mostowicz, M. Dygas and Z. Kaluza, *J. Org. Chem.*, 2015, **80**, 1957.
- For the synthesis of α,β -unsaturated γ -butyrolactones, see, for example: (a) Y. S. Rao, *Chem. Rev.*, 1976, **76**, 625; (b) M. Pohmakotr and P. Jarupan, *Tetrahedron Lett.*, 1985, **26**, 2253; (c) P. Deshong, D. R. Sidler and G. A. Slough, *Tetrahedron Lett.*, 1987, **28**, 2233; (d) A. Arcadi, E. Bernocchi, A. Burini, S. Cacchi, F. Marinelli and

- B. Pietroni, *Tetrahedron*, 1988, **44**, 481; (e) J. M. Clough, G. Pattenden and P. G. Wight, *Tetrahedron Lett.*, 1989, **30**, 7469; (f) D. W. Knight, *Contemp. Org. Synth.*, 1994, **1**, 287; (g) J. A. Marshall, G. S. Bartley and E. M. Wallace, *J. Org. Chem.*, 1996, **61**, 5729; (h) J. A. Marshall and M. A. Wolf, *J. Org. Chem.*, 1996, **61**, 3238; (i) W. Yu and H. Alper, *J. Org. Chem.*, 1997, **62**, 5684; (j) M. Pohmakotr, P. Tuchinda, P. Premkaisorn and V. Reutrakul, *Tetrahedron*, 1998, **54**, 11297; (k) E. Yoneda, T. Kaneko, S. Zhang, K. Onitsuka and S. Takahashi, *Org. Lett.*, 2000, **2**, 441; (l) M. Renard and L. A. Ghosez, *Tetrahedron*, 2001, **57**, 2597; (m) N. B. Carter, A. E. Nadany and J. B. Sweeney, *J. Chem. Soc., Perkin Trans. 1*, 2002, 2324; (n) B. Linclau, A. J. Boydell, P. J. Clarke, R. Horan and C. Jaequet, *J. Org. Chem.*, 2003, **68**, 1821; (o) Y.-Z. Chen, L.-Z. Wu, M.-L. Peng, D. Zhang, L.-P. Zhang and C.-H. Tung, *Tetrahedron*, 2006, **62**, 10688; (p) P. Langer, *Synlett*, 2006, 3369; (q) R. M. Patel, V. G. Puranik and N. P. Argade, *Org. Biomol. Chem.*, 2011, **9**, 6312; (r) S. Li, B. Miao, W. Yuan and S. Ma, *Org. Lett.*, 2013, **15**, 977; (s) C. K. Tan, J. C. Er and Y.-Y. Yeung, *Tetrahedron Lett.*, 2014, **55**, 1243; (t) Y. Yamamoto, S. Shibano, T. Kurohara and M. Shibuya, *J. Org. Chem.*, 2014, **79**, 4503; For the synthesis of α,β -unsaturated γ -butyrolactams, see, for example: (u) G. Casiraghi, P. Spanu, G. Rassu, L. Pinna and F. Ulgheri, *J. Org. Chem.*, 1994, **59**, 2906; (v) A. D. Cuiper, M. Brzostowska, J. K. Gawronski, W. J. J. Smeets, A. L. Spek, H. Hiemstra, R. M. Kellogg and B. L. Feringa, *J. Org. Chem.*, 1999, **64**, 2567; (w) M. G. B. Drew, R. J. Harrison, J. Mann, A. J. Tench and R. J. Young, *Tetrahedron*, 1999, **55**, 1163; (x) G. Verniest, S. Boterberg, F. Bombeke, C. V. Stevens and N. D. Kimpe, *Synlett*, 2004, 1059; (y) S. Roy and C. Spino, *Org. Lett.*, 2006, **8**, 939; (z) S. Spiess, C. Berthold, R. Weihofen and G. Helmchen, *Org. Biomol. Chem.*, 2007, **5**, 2357; (aa) M. Daly, K. Gill, M. Sime, G. L. Simpson and A. Sutherland, *Org. Biomol. Chem.*, 2011, **9**, 6761; (ab) Y. Hoshimoto, T. Ohata, Y. Sasaoka, M. Ohashi and S. Ogoshi, *J. Am. Chem. Soc.*, 2014, **136**, 15877; See also: (ac) G. B. Bajracharya, P. S. Koranne, R. N. Nadaf, R. K. M. Gabr, K. Takenaka, S. Takizawa and H. Sasai, *Chem. Commun.*, 2010, **46**, 9064; (ad) X. Jusseau, L. Chabaud and C. Guillou, *Tetrahedron*, 2014, **70**, 2595.
- 6 For oxidative decarboxylation of acids using lead tetraacetate/Cu(OAc)₂, see, for example: (a) R. A. Sheldon and J. K. Kochi, *Org. React.*, 1972, **19**, 279; (b) P. Macchi, W. Jing, R. Guidetti-Grept and R. Keese, *Tetrahedron*, 2013, **69**, 2479; Using lead dioxide, see: (c) D. V. Hertzler, J. M. Berdahl and E. J. Eisenbraun, *J. Org. Chem.*, 1968, **33**, 2008.
- 7 For the conversion of carboxylic acids to olefins by metal-catalyzed decarbonylative elimination reactions, see, for example: (a) J. A. Miller, J. A. Nelson and M. P. Byrne, *J. Org. Chem.*, 1993, **58**, 18; (b) L. J. Gooßen and N. Rodríguez, *Chem. Commun.*, 2004, 724; (c) J. Le Nôtre, E. L. Scott, M. C. R. Franssen and J. P. M. Sanders, *Tetrahedron Lett.*, 2010, **51**, 3712; (d) S. Maetani, T. Fukuyama, N. Suzuki, D. Ishihara and I. Ryu, *Organometallics*, 2011, **30**, 1389; (e) G. A. Kraus and S. Riley, *Synthesis*, 2012, 3003.
- 8 R. G. Johnson and R. K. Ingham, *Chem. Rev.*, 1956, **56**, 219.
- 9 S. Phae-nok, D. Soorukram, C. Kuhakarn, V. Reutrakul and M. Pohmakotr, *Eur. J. Org. Chem.*, 2015, 2879.
- 10 O. O. Orazi, R. A. Corral and H. E. Bertorello, *J. Org. Chem.*, 1965, **30**, 1101.
- 11 (a) K. Kulbitsku, G. Nisnevich and M. Gandelman, *Adv. Synth. Catal.*, 2011, **353**, 1438; (b) X. Jiang, S. Sakthivel, K. Kulbitski, G. Nisnevich and M. Gandelman, *J. Am. Chem. Soc.*, 2014, **136**, 9548.
- 12 (a) S. Iida and H. Togo, *Tetrahedron*, 2007, **63**, 8274; (b) S. Iida and H. Togo, *Synlett*, 2007, 407; (c) V. K. Chaikovskii, V. D. Filimonov, A. A. Funk, V. I. Skorokhodov and V. D. Ogorodnikov, *Russ. J. Org. Chem.*, 2007, **43**, 1291; (d) S. Takahashi and H. Togo, *Heterocycles*, 2008, **76**, 507; (e) A. Moroda, S. Furuyama and H. Togo, *Synlett*, 2009, 1336; (f) S. Iida, R. Ohmura and H. Togo, *Tetrahedron*, 2009, **65**, 6257; (g) S. Takahashi and H. Togo, *Synthesis*, 2009, 2329; (h) S. Furuyama and H. Togo, *Synlett*, 2010, 2325; (i) H. Baba and H. Togo, *Tetrahedron Lett.*, 2010, **51**, 2063; (j) S. Takahashi and H. Togo, *Heterocycles*, 2010, **82**, 593; (k) M. Sidera, A. M. Costa and J. Vilarrasa, *Org. Lett.*, 2011, **13**, 4934; (l) S. Ushijima, K. Moriyama and H. Togo, *Tetrahedron*, 2011, **67**, 958; (m) H. Baba, K. Moriyama and H. Togo, *Synlett*, 2012, 1175; (n) S. Dohi, K. Moriyama and H. Togo, *Tetrahedron*, 2012, **68**, 6557; (o) S. Ushijima, K. Moriyama and H. Togo, *Tetrahedron*, 2012, **68**, 4588; (p) T. Kamei, H. Shibaguchi, M. Sako, K. Toribatake and T. Shimada, *Tetrahedron Lett.*, 2012, **53**, 3894; (q) G. Jakab, A. Hosseini, H. Hausmann and P. R. Schreiner, *Synthesis*, 2013, 1635; (r) H. Shimojo, K. Moriyama and H. Togo, *Synthesis*, 2013, 2155; (s) A. H. Sandtorv and H.-R. Bjørsvik, *Adv. Synth. Catal.*, 2013, **355**, 499; (t) K. Miyagi, K. Moriyama and H. Togo, *Eur. J. Org. Chem.*, 2013, 5886; (u) Y. Takeda, M. Okazaki and S. Minakata, *Chem. Commun.*, 2014, **50**, 10291; (v) Y. Hu, R. Yi, C. Wang, X. Xin, F. Wu and B. Wan, *J. Org. Chem.*, 2014, **79**, 3052.
- 13 (a) M. Pohmakotr, V. Reutrakul and T. Phongpradit, *Chem. Lett.*, 1982, 687; (b) M. Pohmakotr, V. Reutrakul, W. Harnying and P. Tuchinda, *Helv. Chim. Acta*, 2002, **85**, 3792; (c) M. Pohmakotr, N. Yotapan, P. Tuchinda, C. Kuhakarn and V. Reutrakul, *J. Org. Chem.*, 2007, **72**, 5016; (d) M. Tabcheh, M. Baroudi, F. Elomar, A. Elzant, M. Elkhatib and V. Rolland, *Asian J. Chem.*, 2006, **18**, 1771; (e) D. Soorukram, S. Yodwaree, P. Tuchinda, C. Kuhakarn, V. Reutrakul and M. Pohmakotr, *ARKIVOC*, 2012, 21.
- 14 When *N*-iodosuccinimide (NIS) was employed in place of DIH, **3a** was obtained in low yield (57% yield).
- 15 For recent synthesis of trifluoromethylated butenolides, see: (a) H. Xiao, H. Duan, J. Ye, R.-S. Yao, J. Ma, Z.-Z. Yuan and G. Zhao, *Org. Lett.*, 2014, **16**, 5462; (b) C. Masusai, D. Soorukram, C. Kuhakarn, P. Tuchinda, C. Pakawatchai, S. Saithong, V. Reutrakul and M. Pohmakotr, *Org. Biomol. Chem.*, 2013, **11**, 6650; For γ -difluoromethyl α,β -unsaturated γ -butyrolactones, see: (c) A. Issaree, C. Masusai, D. Soorukram, C. Kuhakarn, V. Reutrakul and M. Pohmakotr, *Eur. J. Org. Chem.*, 2015, 3751.